These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 9818652)
21. Erythrocyte complement receptor type 1 (CR1) expression and circulating immune complex (CIC) levels in hydralazine-induced SLE. Mitchell JA; Batchelor JR; Chapel H; Spiers CN; Sim E Clin Exp Immunol; 1987 May; 68(2):446-56. PubMed ID: 2958187 [TBL] [Abstract][Full Text] [Related]
22. Mannose-binding lectin is a disease-modifying factor in North American patients with systemic lupus erythematosus. Piao W; Liu CC; Kao AH; Manzi S; Vogt MT; Ruffing MJ; Ahearn JM J Rheumatol; 2007 Jul; 34(7):1506-13. PubMed ID: 17610319 [TBL] [Abstract][Full Text] [Related]
24. Reduced complement-mediated immune complex solubilizing capacity and the presence of incompletely solubilized immune complexes in SLE sera. Baatrup G; Petersen I; Jensenius JC; Svehag SE Clin Exp Immunol; 1983 Nov; 54(2):439-47. PubMed ID: 6652967 [TBL] [Abstract][Full Text] [Related]
25. [Atherogenic cholesterol-containing circulating immune complexes--one of the components of the serum in patients with systemic lupus erythematosus]. Gerasimova EV; Alekberova ZS; Popkova TV; Sobenin IA Klin Med (Mosk); 2003; 81(9):39-41. PubMed ID: 14598590 [TBL] [Abstract][Full Text] [Related]
26. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Kirou KA; Lee C; George S; Louca K; Peterson MG; Crow MK Arthritis Rheum; 2005 May; 52(5):1491-503. PubMed ID: 15880830 [TBL] [Abstract][Full Text] [Related]
27. [Study on genetic susceptibility of the single nucleotide polymorphism of FCGR3A gene and systemic lupus erythematosus]. Pan FM; Zhang KC; Li XP; Xu JH; Chen H; Wang Y; Ye DQ Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Oct; 24(5):544-7. PubMed ID: 17922423 [TBL] [Abstract][Full Text] [Related]
28. Fcgamma receptor polymorphisms in systemic lupus erythematosus: association with disease and in vivo clearance of immune complexes. Dijstelbloem HM; Bijl M; Fijnheer R; Scheepers RH; Oost WW; Jansen MD; Sluiter WJ; Limburg PC; Derksen RH; van de Winkel JG; Kallenberg CG Arthritis Rheum; 2000 Dec; 43(12):2793-800. PubMed ID: 11145038 [TBL] [Abstract][Full Text] [Related]
29. Deficiency of functional mannose-binding lectin is not associated with infections in patients with systemic lupus erythematosus. Bultink IE; Hamann D; Seelen MA; Hart MH; Dijkmans BA; Daha MR; Voskuyl AE Arthritis Res Ther; 2006; 8(6):R183. PubMed ID: 17166254 [TBL] [Abstract][Full Text] [Related]
30. Immune complex clearance by complement receptor type 1 in SLE. Kavai M Autoimmun Rev; 2008 Dec; 8(2):160-4. PubMed ID: 18602499 [TBL] [Abstract][Full Text] [Related]
32. Serum amyloid P component-DNA complexes are decreased in systemic lupus erythematosus. inverse association with anti-dsDNA antibodies. Voss A; Nielsen EH; Svehag SE; Junker P J Rheumatol; 2008 Apr; 35(4):625-30. PubMed ID: 18278838 [TBL] [Abstract][Full Text] [Related]
33. Both Fcgamma and complement receptors mediate transfer of immune complexes from erythrocytes to human macrophages under physiological flow conditions in vitro. Hepburn AL; Mason JC; Wang S; Shepherd CJ; Florey O; Haskard DO; Davies KA Clin Exp Immunol; 2006 Oct; 146(1):133-45. PubMed ID: 16968408 [TBL] [Abstract][Full Text] [Related]
34. An enzyme based assay for the measurement of complement mediated binding of immune complexes to red blood cells. Rafnar BO; Traustadóttir KH; Sigfússon A; Arason GJ; Valdimarsson H; Erlendsson K J Immunol Methods; 1998 Feb; 211(1-2):171-81. PubMed ID: 9617841 [TBL] [Abstract][Full Text] [Related]
35. Expression of Fcgamma and complement receptors on peripheral blood monocytes in systemic lupus erythematosus and rheumatoid arthritis. Hepburn AL; Mason JC; Davies KA Rheumatology (Oxford); 2004 May; 43(5):547-54. PubMed ID: 14747618 [TBL] [Abstract][Full Text] [Related]
36. Anti-lipoprotein lipase antibodies: a new player in the complex atherosclerotic process in systemic lupus erythematosus? de Carvalho JF; Borba EF; Viana VS; Bueno C; Leon EP; Bonfá E Arthritis Rheum; 2004 Nov; 50(11):3610-5. PubMed ID: 15529371 [TBL] [Abstract][Full Text] [Related]
37. The spectrum of apoptotic defects and clinical manifestations, including systemic lupus erythematosus, in humans with CD95 (Fas/APO-1) mutations. Vaishnaw AK; Toubi E; Ohsako S; Drappa J; Buys S; Estrada J; Sitarz A; Zemel L; Chu JL; Elkon KB Arthritis Rheum; 1999 Sep; 42(9):1833-42. PubMed ID: 10513797 [TBL] [Abstract][Full Text] [Related]
38. The clinical characterisation of systemic lupus erythematosus in a Far North Queensland Indigenous kindred. Mason JA; Bossingham D Lupus; 2009 Feb; 18(2):144-8. PubMed ID: 19151116 [TBL] [Abstract][Full Text] [Related]
39. The association between systemic lupus erythematosus and deficiencies of the complement system. Goerg S Cell Mol Biol (Noisy-le-grand); 2002 May; 48(3):237-45. PubMed ID: 12030427 [TBL] [Abstract][Full Text] [Related]
40. Fcgamma receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility. Kyogoku C; Dijstelbloem HM; Tsuchiya N; Hatta Y; Kato H; Yamaguchi A; Fukazawa T; Jansen MD; Hashimoto H; van de Winkel JG; Kallenberg CG; Tokunaga K Arthritis Rheum; 2002 May; 46(5):1242-54. PubMed ID: 12115230 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]